- Avista Healthcare Partners has acquired Trillium Health Care Products, a CDMO in North America.
Avista Healthcare Partners (“Avista”), formerly Avista Capital Partners, has announced the completion of its acquisition of Trillium Health Care Products (“Trillium”). Trillium is a contract development and manufacturing organisation (CDMO) specialising in branded over-the-counter (OTC) products in North America. The transaction terms were not disclosed.
Based in Brockville, Ontario, Canada, Trillium is recognised as a trusted partner for leading North American and global consumer healthcare and pharmaceutical companies. The company offers comprehensive development and manufacturing capabilities across liquid, semi-solid, and solid dosage forms. Trillium has extensive experience in therapeutic categories such as cough and cold, dermatology, gastrointestinal, allergy, and dietary supplements.
Alex Yu, Partner at Avista, stated, “Our acquisition of Trillium represents another exciting investment for Avista in the attractive consumer healthcare sector. Trillium is a best-in-class, full-service CDMO with an outstanding reputation in the industry. We had been tracking Trillium for a number of years prior to this acquisition and are delighted to finally partner with Joe and the rest of the Trillium management team to help drive the next phase of the company’s growth.”
Joe Ruffo, CEO of Trillium, expressed enthusiasm about the partnership, saying, “We are thrilled to be partnering with Avista, a growth-oriented partner with sector expertise in consumer healthcare. We see significant market opportunities ahead for Trillium, and are excited to work with Avista to invest in growth and expand our footprint and capabilities to deliver even more value to our customers.”
Fred Duchin, Avista Strategic Executive, added, “Trillium is truly a differentiated provider in the OTC CDMO industry. Their technical expertise, blue-chip customer base, portfolio of market-leading brands, and track record for quality and regulatory compliance is unique. Additionally, we see an opportunity to leverage Trillium as a platform for strategic acquisitions which will only enhance Trillium’s value proposition to the industry.”
Trillium is the sixth investment from Avista’s most recent fund, Avista Healthcare Partners III, following prior investments in WellSpring Consumer Healthcare, Taconic Biosciences, Spear Education, United BioSource, and Terrats Medical. Trillium is also Avista’s sixth consumer healthcare platform, with other portfolio companies including WellSpring Consumer Healthcare, Arcadia Consumer Healthcare, Vision Healthcare, Cooper Consumer Health, and Trimb Healthcare.
 Overview of outsourcing trends 
